International Journal of Cancer Management

Published by: Kowsar

Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance

Reza Ranjbar 1 , Foroogh Nejatollahi 2 , 3 , * , Ahmad Sina Nedaei Ahmadi 2 , Hossein Hafezi 2 and Akbar Safaie 4
Authors Information
1 Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Shiraz HIV/AIDS Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: August 28, 2015, 8 (4); e3428
  • Published Online: August 24, 2015
  • Article Type: Research Article
  • Received: July 6, 2015
  • Accepted: July 12, 2015
  • DOI: 10.17795/ijcp-3428

To Cite: Ranjbar R, Nejatollahi F, Nedaei Ahmadi A S, Hafezi H, Safaie A. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance, Int J Cancer Manag. 2015 ; 8(4):e3428. doi: 10.17795/ijcp-3428.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29[DOI][PubMed]
  • 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 3. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005; 8(2): 169-82[DOI][PubMed]
  • 4. Arab M, Khayamzadeh M, Tehranian A, Tabatabaeefar M, Hosseini M, Anbiaee R, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer. 2010; 47(3): 322-7[DOI][PubMed]
  • 5. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol. 2011; 35(5)-7[DOI][PubMed]
  • 6. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004; 3(4): 355-66[DOI][PubMed]
  • 7. Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Arch Gynecol Obstet. 2013; 288(4): 859-65[DOI][PubMed]
  • 8. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, et al. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer. 2008; 8: 295[DOI][PubMed]
  • 9. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004; 98(7): 632-6[PubMed]
  • 10. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer. 2009; 100(1): 1-7[DOI][PubMed]
  • 11. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010; 16(21): 5320-8[DOI][PubMed]
  • 12. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol. 2008; 109(3): 411-7[DOI][PubMed]
  • 13. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011; 1(6): 524-38[DOI][PubMed]
  • 14. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer. 2011; 11: 294[DOI][PubMed]
  • 15. Landen CJ, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008; 26(6): 995-1005[DOI][PubMed]
  • 16. Grazio D, Pichler I, Fuchsberger C, Zolezzi F, Guarnieri P, Heidegger H, et al. Differential gene expression analysis of ovarian cancer in a population isolate. Eur J Gynaecol Oncol. 2008; 29(4): 357-63[PubMed]
  • 17. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours. 1973;
  • 18. Yao G, He P, Chen L, Hu X, Gu F, Ye C. MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis. Cancer Cell Int. 2013; 13(1): 98[DOI][PubMed]
  • 19. Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha TZ, Feng YZ, et al. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol. 2013; 19(13): 2073-9[DOI][PubMed]
  • 20. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004; 14(2): 259-70[DOI][PubMed]
  • 21. Roskoski RJ. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007; 62(3): 179-213[DOI][PubMed]
  • 22. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000; 83(2): 196-203[DOI][PubMed]
  • 23. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 2004; 14(5): 815-23[DOI][PubMed]
  • 24. Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol. 2002; 84(1): 47-52[DOI][PubMed]
  • 25. Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer. 2004; 14(1): 82-8[PubMed]
  • 26. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res. 2008; 14(10): 3030-5[DOI][PubMed]
  • 27. Siddiqui GK, Elmasry K, Wong Te Fong AC, Perrett C, Morris R, Crow JC, et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. Eur J Gynaecol Oncol. 2010; 31(2): 156-9[PubMed]
  • 28. Comsa S, Cоmpean M, Ceauşu R, Suciu C, Raica M. Correlations between vascular endothelial growth factor expression, microvascular density in tumor tissues and TNM staging in breast cancer. Archives of Biological Sciences. 2012; 64(2): 409-17[DOI]
  • 29. Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation. 2007; 84(12): 1563-7[DOI][PubMed]
  • 30. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997; 80(1): 98-106[PubMed]
  • 31. Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013; 128(2): 391-6[DOI][PubMed]
  • 32. Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer. 2013; 13: 599[DOI][PubMed]
  • 33. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002; 8(11): 3454-60[PubMed]
  • 34. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007; 31(7): 1458-68[DOI][PubMed]
  • 35. Dziadziuszko R, Jassem J. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Ann Oncol. 2012; 23: 193-6
  • 36. Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 2008; 27(3): 380-9[DOI][PubMed]
  • 37. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005; 11(24 Pt 1): 8637-43[DOI][PubMed]
  • 38. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer. 2004; 91(3): 470-5[DOI][PubMed]
  • 39. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl). 2006; 84(8): 671-81[DOI][PubMed]
  • 40. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Modern Pathol. 2006; 19(4): 607-10
  • 41. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther. 2011; 11(1): 50-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments